Welcome to our dedicated page for Ambrx Biopharma news (Ticker: AMAM), a resource for investors and traders seeking the latest updates and insights on Ambrx Biopharma stock.
Ambrx Biopharma Inc. (NASDAQ: AMAM) is a clinical-stage biopharmaceutical company pioneering the development of next-generation antibody drug conjugates (ADCs) and other engineered therapies aimed at modulating the immune system. Utilizing its proprietary expanded genetic code technology platform, Ambrx is at the forefront of creating innovative treatments for multiple cancer indications.
The company's flagship product, ARX517, is a prostate-specific membrane antigen (PSMA)-targeting ADC, specifically developed to treat metastatic castration-resistant prostate cancer (mCRPC). Recently, ARX517 received Fast Track designation from the U.S. Food and Drug Administration (FDA), underscoring its potential as a novel therapy for advanced prostate cancer. The ongoing Phase 1/2 study, APEX-01, has shown promising early efficacy signals with notable PSA reductions and minimal off-target toxicity.
Additionally, Ambrx's portfolio includes ARX788, targeting human epidermal growth factor receptor 2 (HER2) for metastatic breast cancer, and ARX305, targeting CD-70 for renal cell carcinoma. These programs highlight Ambrx's commitment to addressing high unmet medical needs in oncology.
In June 2023, Ambrx successfully closed a $75 million market-priced registered direct offering, bolstering its financial position to $237.4 million in cash, cash equivalents, and marketable debt securities as of May 31, 2023. This funding is primarily allocated to the research and development of its product candidates, working capital, and general corporate purposes.
Ambrx's technology platform, born out of The Scripps Research Institute, enables precise and stable conjugation of synthetic amino acids into proteins, creating homogenous ADCs with enhanced stability and specificity. This technology sets the stage for the development of safer and more effective cancer treatments. Collaborations with multiple partners further amplify the impact of Ambrx's innovations.
Looking ahead, Ambrx's strategic vision and robust pipeline position it as a key player in the biotech landscape. The company is poised to continue its trajectory of growth and innovation, offering hope and improved outcomes for patients with cancer.
Ambrx Biopharma Inc. (NYSE: AMAM) announced that its Chairman, President, and CEO, Feng Tian, Ph.D., will participate in two investor conferences in June. He will engage in a fireside chat at Cowen’s 3rd Annual Oncology Innovation Summit on June 2 at 11:30 AM PT and present at the JMP Securities Life Sciences Conference on June 16 at 11:00 AM PT. Interested parties can access webcasts through the company’s website, with replays available for 90 days. Ambrx focuses on Engineered Precision Biologics, advancing various therapeutic programs, including its lead product candidate ARX788.
Ambrx Biopharma Inc. (NYSE: AMAM) has appointed Dr. Janice Lu as Chief Medical Officer. With over 18 years of experience in clinical trials and breast cancer drug development, Dr. Lu aims to enhance the progress of ARX788 through clinical operations. Her prior roles include Clinical Professor of Medicine at the University of Southern California and Director of Breast Medical Oncology at SUNY Stony Brook. The company focuses on Engineered Precision Biologics and is advancing a strong portfolio of clinical programs.
Ambrx Biopharma Inc. (NYSE: AMAM) has announced that Feng Tian, Ph.D., will present at two investor conferences in May. At the Bank of America 2022 Healthcare Conference, he will participate in a fireside chat on May 11 at 12:00 PM PT. Dr. Tian will also have a pre-recorded presentation at the H.C. Wainwright Global Investment Conference on May 24 at 4:00 AM PT. Interested parties can access the webcasts via www.Ambrx.com. Ambrx focuses on developing Engineered Precision Biologics for various therapeutic areas.
Ambrx Biopharma Inc. (NYSE: AMAM) has filed its annual report on Form 20-F with the SEC for the year ended December 31, 2021. The report, which includes audited consolidated financial statements, is available on both the SEC and company websites. Ambrx utilizes an expanded genetic code technology platform to develop Engineered Precision Biologics, focusing on antibody drug conjugates and immuno-oncology therapies. The company offers a free hard copy of the annual report upon request to shareholders.
Ambrx Biopharma Inc. (NYSE: AMAM) reported a net loss of $68.1 million for the full year ended December 31, 2021, up from $16.5 million in 2020. Revenue decreased to $7.5 million, down from $13.7 million the previous year, primarily due to reduced R&D and licensing revenue. R&D expenses surged to $54.8 million due to increased clinical trial costs, while G&A expenses rose to $17.1 million owing to IPO preparations. Notable advancements include ARX788's participation in I-SPY 2.2 trials and the acceptance of IND for ARX305 by the FDA, with several clinical trials anticipated in 2022.
Ambrx Biopharma (NYSE: AMAM) announces its antibody drug conjugate ARX788 has been selected for the I-SPY 2.2 TRIAL aimed at treating HER2-positive breast cancer. The trial, managed by Quantum Leap Healthcare Collaborative, will evaluate ARX788 as a monotherapy and in combination with cemiplimab. Expected to start patient enrollment in May 2022, the trial seeks to personalize treatment protocols. ARX788 has also received FDA Fast Track Designation for HER2-positive metastatic breast cancer, emphasizing its potential in targeted cancer therapies.
Ambrx Biopharma Inc. (NYSE: AMAM) announced it will release its full year 2021 financial results on
Ambrx Biopharma Inc. (NYSE: AMAM) announced that its CEO, Dr. Feng Tian, will present at the Oppenheimer’s 32nd Annual Healthcare Conference from March 15-17, 2022. Dr. Tian is scheduled to speak on March 17 at 12:40 p.m. Eastern Time. Investors can access the live webcast via the company's website, with a replay available for 90 days post-event. Ambrx focuses on developing Engineered Precision Biologics utilizing an expanded genetic code technology platform, targeting various therapeutic areas including antibody drug conjugates and immuno-oncology.
Ambrx Biopharma Inc. (NYSE: AMAM) announced participation by Dr. Feng Tian, Chairman, President, and CEO, at the Cowen 42nd Annual Health Care Conference from March 7-9, 2022. Dr. Tian will join a corporate panel discussion on ‘Breast Cancer’ on March 9 at 2:10 p.m. Eastern Time. Interested investors can access the live webcast via the company's website, with a replay available for 30 days post-event. Ambrx focuses on developing Engineered Precision Biologics, including next-generation therapies for various diseases.
Ambrx Biopharma Inc. (NYSE: AMAM) has received a "Study May Proceed" letter from the U.S. FDA for its ARX305 Investigational New Drug (IND) application. This anti-CD70 antibody drug conjugate targets various tumors, including renal cell carcinoma. The cleared Phase 1 study aims to evaluate ARX305's safety and preliminary efficacy in patients resistant to standard treatments. This marks Ambrx's third ADC program to advance in clinical development, reflecting their innovative Engineered Precision Biologics platform.
FAQ
What is the market cap of Ambrx Biopharma (AMAM)?
What is Ambrx Biopharma Inc. known for?
What are the key products of Ambrx Biopharma Inc.?
What recent financial achievements has Ambrx reported?
What makes Ambrx's ADC technology unique?
Has Ambrx received any recent regulatory designations for its products?
What clinical trials are currently underway for Ambrx's products?
How does Ambrx's financial standing support its R&D efforts?
What are the main focus areas of Ambrx's current research and development?
What potential does Ambrx's ARX517 have in cancer treatment?
What is the strategic vision for Ambrx Biopharma Inc.?
